Last reviewed · How we verify
vandetanib induction
At a glance
| Generic name | vandetanib induction |
|---|---|
| Also known as | ZD6474 |
| Sponsor | PrECOG, LLC. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery (PHASE1)
- Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors (PHASE1, PHASE2)
- Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer (PHASE2)
- ZD6474 in Treating Patients With Small Cell Lung Cancer (PHASE2)
- Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- vandetanib induction CI brief — competitive landscape report
- vandetanib induction updates RSS · CI watch RSS
- PrECOG, LLC. portfolio CI